Revive Pharmaceuticals Inc. is a company.
Key people at Revive Pharmaceuticals Inc..
Revive Pharmaceuticals Inc. was founded by Cainon Coates (Co-Founder & Operating Partner).
Key people at Revive Pharmaceuticals Inc..
Revive Pharmaceuticals Inc. was founded by Cainon Coates (Co-Founder & Operating Partner).
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing next-generation therapeutics for unmet needs in central nervous system (CNS), respiratory, inflammatory, and cardiometabolic diseases.[1][2] Its lead product candidate, brilaroxazine (RP5063), targets neuropsychiatric conditions like schizophrenia, bipolar disorder, and Alzheimer's-related symptoms, with Phase 3 success in schizophrenia demonstrated in 2023; it's also advancing for respiratory indications and psoriasis, while RP1208 addresses depression and obesity.[1][2] Headquartered in Cupertino, California, with 14 employees and led by CEO Laxminarayan Bhat, the company leverages in-house chemical genomics technology and holds composition-of-matter patents in the US, Europe, and beyond.[1][2]
The firm serves patients with severe mental health and chronic diseases, solving problems like inadequate efficacy, side effects, and limited options in current treatments through novel, once-daily therapies showing consistent efficacy and safety across trials.[2]
Founded in 2018 (with some sources noting earlier roots around 2006), Reviva emerged from in-house discovery using a chemical genomics-driven platform to create new chemical entities like brilaroxazine and RP1208.[1][2] CEO Laxminarayan Bhat leads the small team of 14, based in Cupertino, California, focusing on biopharma innovation without detailed public backstory on initial founders or pivotal early moments beyond pipeline development.[1] A key milestone was the October 2023 announcement of positive Phase 3 RECOVER trial results for brilaroxazine in schizophrenia, meeting all endpoints and building on Phase 2 REFRESH data, marking late-stage progress toward commercialization.[2]
Reviva rides the wave of precision biopharma innovation in CNS and neuropsychiatric disorders, where demand surges amid aging populations, rising mental health crises, and failures of existing antipsychotics with metabolic side effects.[1][2] Timing aligns with post-pandemic emphasis on schizophrenia treatments—market projected to grow as novel modalities like partial agonists gain traction—bolstered by FDA fast-track potentials and patent exclusivity.[2] Positive Phase 3 data positions Reviva to influence the ecosystem by challenging incumbents like Abilify or Rexulti, potentially expanding into respiratory/inflammatory markets amid biotech M&A trends favoring late-stage assets.[1][2]
Reviva's path hinges on brilaroxazine NDA filing post-Phase 3 success, likely targeting 2026 approval and launch in schizophrenia, with label expansions into bipolar, respiratory, and beyond driving revenue.[2] Trends like AI-driven discovery (echoing their genomics platform) and obesity/depression combo therapies will shape growth, amid biotech funding recovery and Big Pharma partnerships.[1][2] Influence may evolve from developer to market player, capturing share in a $10B+ schizophrenia space if safety edges hold, tying back to its mission of transformative CNS therapies.[1][2]
